Rituximab review- Reduced disease activity in multiple sclerosis patients

Two new studies have shown that Rituximab does reduce disease activity in people with relapsing-remitting form of multiple sclerosis (MS).

Rituximab is the drug that has been found to selectively target and deplete a subset of immune cells called B-cells by targeting a very specific protein on the cell surface.

Rituximab is one of the the first drugs designed to target B-cells. Rituximab offer a new treatment for relapsing multiple sclerosis.